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Biotherapy Translational Medicine Center of West China 
Hospital, Sichuan University is one of the research centers 
in West China Hospital, which is located in High Tech Zone, 
Chengdu. It includes several core facilities, such as State 
Key Laboratory of Biotherapy/one of the National Research 
and Development (R&D) Platforms for Novel Drugs, 
Chengdu National New Drug Pre-Clinical Safety Evaluation 
Center and GCP Center of West China Hospital. State Key 
Laboratory of Biotherapy was established by Ministry of 
Science and Technology of China in 2005, and it became 
one of the National R&D Platforms for Novel Drugs 
founded by Ministries of Science and Technology as well as 
Public Health in September 2008. It is also supported by 
national collaborative innovation and it became the collab-
orative innovation center for biotherapy in April 2013, 
which is located at Medical Campus of Sichuan University.  
Biotherapy Translational Medicine Center of West China 
Hospital is becoming a highly-regarded, comprehensive and 
multidisciplinary research center (Figure 1). Through the 
seamless integration of basic research, preclinical develop-
ment, translational and clinical medicine, an efficient and 
fully integrated technology chain for the discovery and de-
velopment of innovative drug candidates and new therapy 
has been established in a single institute. One mission of 
this center is to improve the treatment of major human dis-
eases such as cancer, cardiovascular diseases, obesity, dia-
betes mellitus, infectious diseases (hepatitis, AIDS, tuber-
culosis, etc.), inflammatory diseases, neurological disease, 
as well as chronic autoimmune diseases. Focusing on more 
than 150 important targets, hundreds of projects for biologic 
drugs (such as gene and cell therapy, vaccines, monoclonal 
antibodies, recombinant proteins), synthetic small molecule 
drugs and small molecule natural products are ongoing.  
The center boasts a prominent faculty of nearly 100 
well-funded full professors, associate professors and assis-
tant professors with diverse disciplines such as clinical 
medicine, biotechnology, structural biology, immunology, 
pharmacology, chemistry, formulations, drug delivery and 
material sciences. Every year the faculty obtains competi-
tive grants from the government, including the National 
High Technology Research and Development Program (863 
Program) or the Major State Basic Research Development 
Program (973 Program). Over 400 research papers are pub-
lished in peer-reviewed international journals every year, 
including such top journals as New Engl J Med, Nat Rev 
Drug Discovery, Dev Cell, Nat Chemical Biol, Nature Med, 
Mol Cell, Proc Natl Acad Sci USA, Cancer Res and Lancet 
Neurol. To date, the platform has licensed over 150 patents 
to the commercial sector throughout China. Furthermore, 45 
potent candidate drugs, including synthetic and natural 
small molecular drugs, gene and cell therapy, vaccine, 
monoclonal antibodies and recombinant proteins, thus far 
have been transferred to over 30 pharmaceutical companies 
for commercial development. The candidate drugs are those 
for the treatment of cancer, diabetes, autoimmune diseases, 
fibrosis, Hepatitis B/C and HIV.  
The platform also provides both key technological ser-
vices and integral solutions in R&D for other institutions 
and companies, including: 
(1) Drug target identification and drug screening. The 
platform has established multiple sub-platforms for R&D 
screening of novel molecules, such as genomics, proteomics,   
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Figure 1  (Color online) Translational Medicine Center of West China Hospital. A, Technical mapping for translational medicine research. B, National 
Research and Development Platform for Innovative Drugs (Biotherapy Translational Medicine Center of West China Hospital) in High Tech Zone, Chengdu, 
China. C, National Research and Development Platform for Innovative Drugs (Biotherapy Translational Medicine Center of West China Hospital) in Medi-
cal Campus, Chengdu, China. D, Clinical Translational Center of West China Hospital for Innovative Drugs (Biotherapy Translational Medicine Center of 
West China Hospital) in Chengdu, China. 
structural biology, bioinformatics, computer-aided drug 
design, screening and synthesis of small molecule chemical 
drugs and the separation and purification of active natural 
products. 
(2) Pilot-scale production. Six GMP-level facilities for 
pilot-scale production of adenoviral vectors, vaccines, DNA 
plasmids, recombinant proteins and nanoparticles have been 
established. For example, the pilot-scale production of DNA 
plasmids provides 5,0008,000 doses for early phase clini-
cal trials.  
(3) Pharmacodynamics & pharmacokinetics. Three sepa-
rate experimental animal facilities can maintain up to 
60,000 mice. At full capacity, 300 drug candidates can be 
evaluated at the same time. To date, there have been over 
100 different preclinical disease models established at these 
facilities.  
(4) Pre-clinical safety evaluation. The animal center has 
currently obtained international “AAALAC” accreditation.  
The GLP facility can maintain up to 500 monkeys. Various 
toxicity studies including single dose toxicity, repeated dose 
toxicity, reproductive and developmental toxicity, genotox-
icity, carcinogenicity, immunogenicity and pharmacokinet-
ic/toxicokinetic (PK/TK) analyses are all performed.  
(5) Clinical trials. Clinical trials testing gene and cell 
therapy, cytokines and anti-cytokines, monoclonal antibod-
ies, chemotherapy and targeted small molecule drugs are 
conducted in the clinical units of West China Hospital with 
4,300 beds.  
(6) Graduate programs. The platform also is an educa-
tional center. Every year the platform enrolls about 150 
Ph.D. and 100 M.S. students for different academic pro-
grams, as well as nearly 100 M.S. graduate students for 
pharmaceutical engineering programs.  
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